scispace - formally typeset
J

James Brian Byrd

Researcher at University of Michigan

Publications -  83
Citations -  3195

James Brian Byrd is an academic researcher from University of Michigan. The author has contributed to research in topics: Angioedema & Angiotensin-converting enzyme. The author has an hindex of 20, co-authored 79 publications receiving 2108 citations. Previous affiliations of James Brian Byrd include Vanderbilt University Medical Center & University of Colorado Denver.

Papers
More filters
Journal ArticleDOI

EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research

Jan Van Deun, +101 more
- 01 Mar 2017 - 
TL;DR: It is argued that the field of extracellular vesicle (EV) biology needs more transparent reporting to facilitate interpretation and replication of experiments and EV-TRACK, a crowdsourcing knowledgebase that centralizes EV biology and methodology, is described.
Journal ArticleDOI

Privacy-Preserving Generative Deep Neural Networks Support Clinical Data Sharing.

TL;DR: This research presents a novel probabilistic approach that allows us to assess the importance of knowing the carrier and removal status of canine coronavirus, as a source of infection for other animals.
Journal ArticleDOI

Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.

TL;DR: The REPLACE COVID trial as mentioned in this paper evaluated whether continuing versus discontinuing renin-angiotensin system inhibitors (ANGI-converting enzyme inhibitors or angiotENSin receptor blockers) affects outcomes in patients admitted to hospital with COVID-19.
Journal ArticleDOI

Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema

TL;DR: The remitting and relapsing nature of ACE inhibitor-associated angioedema can confound clinical recognition of the adverse event but also provides clues to its causes.

Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor-associated angioedema

TL;DR: This case-control study tested the hypothesis that dipeptidyl peptidase IV activity and antigen are decreased in sera of patients with a history of angiotensin-converting enzyme inhibitor–associated angioedema, and found that it was true.